Investigational drug · Phase 2
ASCA101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cachexia; Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "ASCA101"
First trial start
2026
May 8, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ASCA101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Cachexia; Cancer
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ASCA101" as an intervention, largest first.
- Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101Pivotal-lookingRecruiting
MetaFinesIndustry
NCT07168226 · 135 participants (planned) · Start May 8, 2026 · Primary completion Apr 30, 2028
Drug: Active Comparator; ASCA101 24.32mg/kg and 2 more · For: Cachexia; Cancer
Sites: Seoul, South Korea; Gyeonggi-do, South Korea · 6 sites in all
MetaFinesIndustry
NCT05547906 · 18 participants · Start Nov 8, 2021 · Primary completion Feb 29, 2024
Drug: ASCA101 · For: Solid Tumor
Sites: Los Angeles, California; Seongnam-si, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Cachexia; Cancer
- RilogrotugPhase 31 trial
AVEO Pharmaceuticals, Inc. · Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.